Newfeed

Highlights from the Data Presentation Initial immunogenicity (n=9) and ongoing safety data (n=13) presented in chronically HBV-infected patients following a single, low dose, prime-only intramuscular injection of VRON-0200VRON-0200 was well tolerated, with no serious adverse events (SAEs), study pat

Highlights from the Data Presentation Initial immunogenicity (n=9) and ongoing safety data (n=13) presented in chronically HBV-infected patients following a single, low dose, prime-only intramuscular injection of VRON-0200VRON-0200 was well tolerated, with no serious adverse events (SAEs), study pat

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: